We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » PhRMA Rejects GPhA’s Call For Same-Name Biosimilars
PhRMA Rejects GPhA’s Call For Same-Name Biosimilars
PhRMA has placed itself in the middle of a mounting battle over biosimilar naming, calling on the FDA to deny GPhA’s petition for same-name biosimilars and arguing that distinguishable, yet related names are “essential” for adverse event reporting.